BRASILIA—Brazilian health regulator Anvisa has canceled a request for emergency use authorization for the COVID-19 vaccine developed by China’s CanSino Biologics Inc. after the laboratory cut ties with its Brazilian representative.
The move follows a wave of scrutiny in Brazil of vaccine contracts negotiated by intermediaries, a common local practice.
